February 20, 2020
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs
PLANO, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results ...
February 20, 2020
Adverum Biotechnologies to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and ...
February 20, 2020
Altimmune to Present at the Cowen 40th Annual Health Care Conference
GAITHERSBURG, Md., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that Vipin K. Garg, Ph.D., President and Chief ...
February 20, 2020
Axovant Gene Therapies Announces Pricing of $65 Million Public Offering
NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (AXGT) ("Axovant") today announced the pricing of its underwritten public ...
February 20, 2020
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to ...
February 20, 2020
Compugen Reports Fourth Quarter and Full Year 2019 Results
HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results ...
February 20, 2020
VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer
TEL AVIV, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT) today announced the launch of a phase 2 clinical trial of VB-111 in ...
February 20, 2020
miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
February 20, 2020
BioDelivery Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
RALEIGH, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious ...
February 20, 2020
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs
OTTAWA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (TBPMF) ...
February 20, 2020
Genocea to Present at the SVB Leerink 9th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president ...
February 20, 2020
Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today ...
February 19, 2020
Pixium Vision announces issue of € 1.25 million new tranche from ESGO financing agreement to continue to accelerate its clinical programs
Paris, 19 February 2020 – 7.00 am CEST– Pixium Vision (FR0011950641 - ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients ...
February 19, 2020
CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection
MONMOUTH JUNCTION, N.J. and NORTH POINT, Hong Kong, Feb. 19, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader with more than 80,000 global ...
February 19, 2020
Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma
AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery ...
February 19, 2020
Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643
CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate ...
February 19, 2020
Arcturus Therapeutics to Present at Two Investor Conferences in March
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development ...
February 19, 2020
DarioHealth® Presents New Clinical Study Outcomes Showing the Dario Digital Therapeutics Platform Helps Insulin Dependent Patients With Diabetes Better Manage Their Chronic Condition
NEW YORK, Feb. 19, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a pioneer in the global digital therapeutics market, today presented a new ...
February 19, 2020
HTG Molecular to Present Corporate Overview at the SVB Leerink 9th Annual Global Healthcare Conference
TUCSON, Ariz., Feb. 19, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, ...
February 19, 2020
Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively ...
Page 179 of 189